Heartflow, Inc. (HTFL) - 10-Q Summary for Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2025. Heartflow, Inc. is a commercial-stage medical technology company utilizing AI and computational fluid dynamics to provide non-invasive solutions for diagnosing and managing coronary artery disease (CAD). The company operates as a single reporting segment. As of the filing date, the company was a private entity preparing for an Initial Public Offering (IPO), which was completed on August 11, 2025, subsequent to the reporting period.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|---|---|
| Revenue | $43,424 | $80,629 | $31,054 | $57,897 |
| Gross Profit | $32,778 | $60,719 | $23,839 | $43,262 |
| Gross Margin | 75.5% | 75.3% | 76.8% | 74.7% |
| Net Loss | $(9,196) | $(41,541) | $(23,379) | $(44,311) |
| Net Loss Per Share (Basic & Diluted) | $(1.46) | $(6.66) | $(4.66) | $(8.89) |
| Cash and Cash Equivalents (as of June 30, 2025) | $80,210 | |||
| Accumulated Deficit (as of June 30, 2025) | $(1,012,500) | |||
| Operating Cash Flow (Six Months) | $(40,470) | $(44,696) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 40% year-over-year for the quarter and 39% for the six-month period, driven primarily by a 47% and 44% increase in revenue case volume, respectively. This growth was partially offset by a reduction in average sales price due to a higher mix of clinic/office-based accounts and increased volume rebates.
- Operating Expenses: Total operating expenses increased 22% for the quarter and 25% for the six-month period. Research and Development (R&D) expenses rose 51% and 49%, respectively, due to increased headcount and clinical trial costs. Selling, General, and Administrative (SG&A) expenses increased 12% and 16%, driven by personnel costs and professional fees.
- Net Loss Improvement: Net loss decreased significantly by 61% for the quarter and 6% for the six-month period compared to the prior year. This improvement was largely attributable to a $11.5 million gain from the remeasurement of derivative liability related to convertible notes, partially offset by a $0.9 million loss on warrant liability remeasurement.
- Debt Structure: The company issued $98.3 million in aggregate principal of 2025 Convertible Notes in January and March 2025. Additionally, $23.0 million of the 2024 Term Loan principal was converted into these notes.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes that existing cash, expected revenue, and net proceeds from the August 2025 IPO will fund operations for at least the next 12 months. The company expects to continue incurring losses as it scales operations and invests in R&D and commercial expansion.
Subsequent Events (Post-June 30, 2025):
- IPO Completion: On August 11, 2025, the company completed its IPO, selling 19,166,667 shares at $19.00 per share, raising approximately $364.2 million in gross proceeds (approx. $332.8 million net).
- Debt Repayment: Following the IPO, the company repaid $55.0 million of the 2024 Term Loan and associated fees. On August 22, 2025, the company prepaid the remaining $60.1 million principal balance of the 2024 Term Loan in full, terminating the credit agreement.
- Conversion: Upon IPO closing, all outstanding 2025 Convertible Notes automatically converted into common stock.
Key Risks:
- Reimbursement: Reliance on third-party payors (including Medicare) for adequate reimbursement. Proposed 2026 Medicare rule changes could reduce reimbursement rates by up to 15%.
- Product Concentration: 98% of revenue is derived from the Heartflow FFR CT Analysis product.
- Profitability: The company has an accumulated deficit of $1.0 billion and expects to incur losses for the foreseeable future.
- Regulatory: Risks associated with FDA and international regulatory approvals for current and future products (e.g., Heartflow Plaque Analysis, Heartflow PCI Planner).
Investor Verification Checklist
- IPO Proceeds Utilization: Verify the actual net proceeds received from the August 2025 IPO and confirm the full repayment of the 2024 Term Loan and 2025 Convertible Notes as disclosed in subsequent filings.
- Reimbursement Rates: Monitor the finalization of the 2026 Medicare OPPS rule to assess the potential 15% reduction in reimbursement rates for Heartflow FFR CT Analysis.
- Revenue Case Growth: Track the quarterly growth in "Heartflow revenue cases" to validate the 47% volume increase reported for Q2 2025 and ensure it is not solely driven by pricing mix changes.
- Derivative Liability Volatility: Review future earnings for volatility in "Other income (expense)" driven by the fair value remeasurement of warrant and derivative liabilities, which significantly impacted the Q2 2025 net loss.
- Plaque Analysis Adoption: Assess the commercial traction of Heartflow Plaque Analysis, which is currently nascent but critical for diversifying the revenue base beyond the 98% reliance on FFR CT Analysis.